A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Study to Evaluate the Safety, Tolerability, And Pharmacokinetics of Gusacitinib in Subjects With Systemic Lupus Erythematosus (SLE)
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Gusacitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- 13 Mar 2025 Status changed from discontinued to withdrawn prior to enrolment.
- 06 Mar 2025 Status changed to discontinued as drug company discontinuing study.
- 28 Feb 2025 Status changed from recruiting to completed.